Drug ID:Drug65
Drug Name:Febuxostat
CID:134018
DrugBank ID:DB04854
Modality:Small Molecule
Groups:NULL
US Approved:YES
Other Approved:YES
Identifier: NCT06525974
Molecular Formula:C16H16N2O3S
Molecular Weight:316.4 g/mol
Isomeric SMILES:CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O
Synonyms:Febuxostat; 144060-53-7; Adenuric; Feburic; TMX-67; TMX 67; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid; Zurig; Donifoxate; Febuxostatum
Phase 0: 1
Phase 1: 21
Phase 2: 40
Phase 3: 26
Phase 4: 22
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt579 134018 Febuxostat 367 AR Homo sapiens (human) None
dt580 134018 Febuxostat 2646 GCKR Homo sapiens (human) Inhibitor
dt581 134018 Febuxostat 7498 XDH Homo sapiens (human) Xanthine dehydrogenase inhibitor
dt582 134018 Febuxostat 7498 XDH Homo sapiens (human) Inhibitor
dt583 134018 Febuxostat 54578 UGT1A6 Homo sapiens (human) None
dt584 134018 Febuxostat 54577 UGT1A7 Homo sapiens (human) None
dt585 134018 Febuxostat 54576 UGT1A8 Homo sapiens (human) None
dt586 134018 Febuxostat 7498 XDH Homo sapiens (human) None
dt587 134018 Febuxostat 177 AGER Rattus norvegicus (Norway rat) 30726711 Febuxostat inhibits the reaction [paraquat results in increased expression of AGER mrna]|febuxostat inhibits the reaction [paraquat results in decreased secretion of AGER protein modified form]
dt588 134018 Febuxostat 581 BAX Rattus norvegicus (Norway rat) 26036690 Febuxostat inhibits the reaction [doxorubicin results in increased expression of BAX protein]

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
ACTRN12612001107819 Febuxostat-thiopurine combination therapy in patients with moderately severe inflammatory bowel disease (IBD): a pilot study of a novel drug combination that may influence thiopurine bioavailability PHASE1 Not Recruiting Prof Tim Florin inflammatory bowel disease; inflammatory bowel d… To use the combination of febuxostat and 6-mercap… Details
NCT06525974 Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine EARLY_PHASE1 NOT_YET_RECRUITING Tanta University Ulcerative Colitis DRUG: Febuxostat|DRUG: Mesalamine Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Role of allopurinol and febuxostat in the amelioration of dextran-induced colit…

PMID: 31654756
Year: 2020
Relationship Type: Treatment Score: 6.5

Ulcerative colitis is a chronic auto-inflammatory disorder confined to the colorectal region. It is challenging to find an absolute treatment and cur…

View Details
Febuxostat attenuates ulcerative colitis by the inhibition of NF-κB, proinflamm…

PMID: 31499267
Year: 2019
Relationship Type: Treatment Score: 6.5

Ulcerative colitis is a chronic inflammatory disorder characterized by oxidative stress and upregulation of proinflammatory mediators in colonic tiss…

View Details